Prior COVID-19 infection offered protection from re-infection for at least six months
On Nov. 20, 2020, the University of Oxford announced a study suggested that individuals who have previously had…
-
-
Avian influenza virus spread rapidly in Europe
On Nov. 20, 2020, the ‘European Food Safety Authority reported that within the past month more than 300…
-
ApiJect approved for $590 million loan from US International DFC to build drug manufacturing facility in North Carolina
On Nov. 19, 2020, ApiJect Systems, a public benefit corporatio, announced that it had been approved by the…
-
Study of ‘exceptional responders’ yields clues to cancer and potential treatments
On Nov. 19, 2020, in a comprehensive analysis of patients with cancer who had exceptional responses to therapy,…
-
Medigen Vaccines announced publication of positive results from preclinical studies of COVID-19 vaccine candidate
On Nov. 19, 2020, Medigen Vaccine Biologics announced that preclinical results of their COVID-19 vaccine candidate had been…
-
Biotechnology | COVID-19 | Diagnostics | HIV
Viruses shown to evolve as a result of different immune responses in different ethnic populations
On Nov. 19, 2020, University of Oxford researchers announced that research into the HIV-1 virus had shed light…
-
Cue’s Molecular, point-of-care COVID-19 tests deployed to five states in HHS and DOD pilot program
On Nov. 19, 2020, Cue Health announced that, as of November 9, the U.S. Department of Health and…
-
Novartis secured exclusive rights for potential acute respiratory distress syndrome cell therapy
On Nov. 19, 2020, Novartis announced that it had entered into an exclusive worldwide license and collaboration agreement…
-
Biotechnology | COVID-19 | FDA | Therapeutics
Baricitinib received Emergency Use Authorization from FDA for treatment of hospitalized patients with COVID-19
On Nov. 19, 2020, Eli Lilly and Incyte announced that the FDA had issued an Emergency Use Authorization…
-
FX06 clinical trial for treatment of most severely affected patients with COVID-19 begun in France
On Nov. 19, 2020, F4 Pharma announced the inclusion of the first patient with severe COVID-19 in a…
-
Artificial Intelligence | Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Medical Device | Therapeutics
Texas A&M System, Worlds Inc. collaborated on COVID-19 breathalyzer
On Nov. 19, 2020, Dallas-based company, Worlds Inc., the U.S. Air Force and Texas A&M University announced a…
-
XBiotech data showed effective anti-virus activity for antibodies in candidate influenza-COVID-19 therapeutic
On Nov. 19, 2020, XBiotech announced data for its breakthrough candidate therapy for treating infections of influenza and…
-
Oxford Coronavirus vaccine produced strong immune response in older adults
On Nov. 19, 2020, the University of Oxford announced that the ChAdOx1 nCov-2019 coronavirus vaccine had been shown…
-
BioVersys announced first subjects dosed in phase 1 clinical trial of BV100
On Nov. 18, 2020, BioVersys announced a milestone by entering clinical development with the start of Phase 1…
-
11th Ebola outbreak in the Democratic Republic of the Congo declared over
On Nov. 18, 2020, marked the end of the 11th Ebola outbreak in the Democratic Republic of the…
-
Relief Therapeutics selected CRO and CDMO for RLF-100TM in Europe
On Nov. 18, 2020, RELIEF THERAPEUTICS announced the appointment of Syneos Healthﾮ, a leading global clinical research organization…
-
Todos Medical announced positive initial clinical proof-of-concept data for rapid SARS-CoV-2 3CL protease detection assay
On Nov. 18, 2020, Todos Medical announced positive clinical proof of concept data from its lab-based rapid SARS-CoV-2…
-
Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 study
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
-
Pfizer and BioNTech announced phase 3 study of COVID-19 vaccine candidate met all efficacy endpoints
On Nov. 18, 2020, Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing…
-
OHSU study screened wastewater, test volunteers for coronavirus
On Nov. 18, 2020, Oregon Health & Science University (OHSU) announced an initiative that will attempt to discern…
-
NIH to fund research of racial disparities in pregnancy-related complications and deaths
On Nov. 17, 2020, the NIH announced funding of new research examining racial and ethnic disparities in pregnancy-related…
-
Overweight and obese younger people at greater risk for severe COVID-19
On Nov. 17, 2020, UT Southwestern researchers reported that being younger doesnﾒt protect against the dangers of COVID-19…
-
Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccine
On Nov. 17, 2020, Celdara Medical announced that the National Institute of Allergy and Infectious Disease (NIAID) of…
-
FDA authorized first COVID-19 test for self-testing at home
On Nov. 17, 2020, the FDA issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test…
-
The US Dept of Veterans Affairs, federal partners plan for COVID-19 vaccination distribution
On Nov. 17, 2020, the U.S. Dept. of Veterans Affairs (VA) announced it was working with the Centers…
-
Bankruptcy judge approved federal settlement with Purdue Pharma
On Nov. 17, 2020, the proposed settlements between the federal government and OxyContin maker Purdue Pharma and its…
-
Moderna announced supply agreement with UK Government to supply mRNA vaccine against COVID-19
On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to…
-
Biotechnology | COVID-19 | FDA | Therapeutics
RedHill’s second COVID-19 candidate cleared by FDA for phase 2/3 Study in symptomatic COVID-19 disease
On Nov. 17, 2020, RedHill Biopharma announced that the U.S. Food and Drug Administration (FDA) had cleared the…
-
Mayo Clinic reported 900 employees contracted COVID-19 from local community
On Nov. 17, 2020, the Mayo Clinic reported that more than 900 employees had contracted COVID-19 in the…
-
Biological E Limited started phase I/II clinical trial of its COVID-19 vaccine candidate
On Nov. 16, 2020, Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies, and Baylor…
